Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
1. Objective : To test the safety of 6 month-duration of dual antiplatelet therapy (DAPT)
compared to conventional 12-month-or-longer duration after second-generation
drug-eluting stent (DES) implantation in patients with acute coronary syndrome (ACS).
2. Hypothesis : A 6-month duration of DAPT is non-inferior to a conventional 12-month-or
longer duration of DAPT at preventing the occurrence of major adverse cardiac and
cerebrovascular events (MACCE) at 18-month after second-generation DES implantation in
patients with ACS.